Nasdaq · Biotech stocks database
DBVT (DBV Technologies S.A.) stock: $10.45, $657.1M market cap, $165.7M cash, $491.6M EV, $882.2M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
Our therapeutic approach is based on epicutaneous immunotherapy, or EPIT, our proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). We have generated significant data demonstrating that Viaskin patch’s mechanism of action is novel and differentiated.
Source: 10-K FY2025 via SEC EDGAR
| Cash | $165.7M |
|---|---|
| Debt | $0.2M |
| Net cash | $165.5M |
| Enterprise value | $491.6M |
| Basic shares | 59.2M shares |
| Fully diluted shares | 84.4M shares |
| Fully diluted market cap | $882.2M |
| Cash per share | $2.80 |
| Quarterly burn | $52.6M |
| Cash runway | 3.3 quarters |
Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.
Cap table as of 2026-07-16.
Loading DBVT daily closes…